Background
Interest in the ASQoL has grown rapidly since the need arose to evaluate the new anti-TNF biological modulators in the treatment of AS.
Abbott was the first major pharmaceutical company to use the ASQoL when evaluating the impact of adalimumab. The company was able to obtain a QoL label from the FDA based on data collected with the ASQoL. van This encouraged other companies to use the ASQoL to show the benefits of their products. For example, the measure has been used to evaluate etenercept in the treatment of AS. In order to make the measure more available the ASQOL was successfully translated into eight languages. Psychometric properties were excellent for US English, Canadian English, and German and extremely promising for the other languages. Authors have shown that disease-specific assessment of patientreported outcomes in AS is more effective than using generic measures. This is because carefully developed disease-specific measures assess all relevant issues and omit others that are not specific to the disease. 
Aim
This poster reports on further developments of the ASQoL.
Quality of life (QoL) is often poorly defined and most 'QoL' measures are not based on a clear theoretical model. In contrast, the needsbased QoL model (see below) used as the basis for the ASQoL has been applied successfully in the development of numerous diseasespecific patient-reported outcome measures.
Patient reported outcome measures (PROMs) are becoming increasingly widely used, especially in clinical trials. Payers now require evidence of patient benefit in addition to the efficacy of interventions.
PROMs used in clinical studies are required to have extremely good psychometric properties including reproducibility, construct validity and responsiveness to changes in health status. It is also now widely accepted that PROMs should also be unidimensional.
The needs-based QoL model is the most operationalised in QoL assessment and research. It considers that the most important aspect of a disease or illness is the impact that impairments and functioning have on patients' ability to meet their needs. For example, a person who is restricted in their ability to walk may become deprived of a number of needs such as their sense of identity, gaining access to exercise and pleasure, participating in work, spending time with friends and family or purchasing essential food. Content for the ASQoL was derived from qualitative interviews conducted with AS patients. Several stages of testing followed the development of a draft version of the measure. These ensured that it was well accepted by patients and that it had good face and content validity, reproducibility and construct validity.
The ASQoL is easy to administer and score and it has been shown to provide a valuable tool for assessing the impact of interventions for AS and for evaluating models of service delivery. The ASQoL takes about four minutes to complete and has excellent scaling and psychometric properties.
Conclusions

